RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
29/10/26	¥66.00	+1.54%	224,800
28/10/26	¥65.00	+1.56%	200,300
27/10/26	¥64.00	-1.54%	209,400
26/10/26	¥65.00	-1.52%	270,000
23/10/26	¥66.00	+1.54%	575,800

Delayed Quote Japan Exchange

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Ribomic Inc.

Company calendar

Market Closed - Japan Exchange 09:30:00 29/10/2026 +03			5-day change	1st Jan Change
66.00 ^JPY	+1.54%		0.00%	-15.38%

10-20	RIBOMIC, Inc. Enters Into Technology Evaluation Agreement For DDS Aptamer Asset With A Biotechnology Company Based Outside Japan	CI
10-06	RIBOMIC, Inc. Announces Interim Report On Phase 2 Long-Term Clinical Trial Of Umedaptanib Pegol In Treatment Of Achondroplasia	CI

Market Cap	3.75B 23.75M 21.28M 19.63M 17.76M 33.21M 2.26B 33.75M 234M 93.42M 1.18B 89.14M 87.25M	P/E 2025	-3.89x	P/E 2026	-3.82x
Enterprise Value	922M 5.84M 5.23M 4.83M 4.37M 8.17M 556M 8.3M 57.61M 22.98M 291M 21.93M 21.46M	EV / Sales 2025	666x	EV / Sales 2026	651x
Free-Float	97.07%	Yield 2025 *	-	Yield 2026	-

10-20	RIBOMIC, Inc. Enters Into Technology Evaluation Agreement For DDS Aptamer Asset With A Biotechnology Company Based Outside Japan	CI
10-06	RIBOMIC, Inc. Announces Interim Report On Phase 2 Long-Term Clinical Trial Of Umedaptanib Pegol In Treatment Of Achondroplasia	CI
09-29	RIBOMIC, Inc. Announces No Safety Concerns After Three Months Of 1 Mg/Kg Weekly Treatment With Umedaptanib Pegol In Achondroplasia Phase 2 Study	CI
08-24	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia	CI
08-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
08-13	Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-02	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
07-02	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia	CI
05-14	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
03-19	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
03-19	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
03-10	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
03-10	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI

07/10/25	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
05/11/24	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
03/08/24	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
05/12/23	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
29/07/22	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Stock

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news: Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08/10/25	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
06/11/24	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20/02/20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19/06/19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 day	+1.54%
Current month	-17.50%
1 month	-14.29%
3 months	-7.04%
6 months	-16.46%
Current year	-15.38%

1 week	63	67
1 month	62	80
Current year	57	120
1 year	57	120
3 years	57	141
5 years	57	944
10 years	57	1,109

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	01/04/2012
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	39	01/10/2023

Director	Title	Age	Since
Yoshikazu Nakamura BRD	Director/Board Member	78	01/10/2005
Toshiaki Nishihata BRD	Director/Board Member	77	01/06/2016
Takeo Adachi BRD	Director/Board Member	39	01/06/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	+1.54%	0.00%	-27.47%	-47.62%	23.34M
WUXI APPTEC CO., LTD.	+0.34%	-3.03%	+37.45%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+83.90%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+105.71%	53.03B
IQVIA HOLDINGS INC.	-2.00%	-1.79%	+25.48%	+54.28%	45.99B
BEONE MEDICINES AG	-1.05%	-3.51%	+17.15%	+97.66%	42.45B
REVOLUTION MEDICINES, INC.	-0.40%	+0.26%	+224.33%	+925.48%	40.45B
CELLTRION, INC.	-0.26%	-4.20%	+10.86%	+45.18%	32.25B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+90.26%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-8.79%	+22.58%	-5.63%	24.23B
Average	-0.42%	+3.29%	+43.97%	+141.03%	39.26B
Weighted average by Cap.	-0.37%	+3.13%	+49.00%	+159.69%

	2025	2026
Net sales	2M 12.67K 11.35K 10.47K 9.47K 17.72K 1.21M 18K 125K 49.83K 631K 47.55K 46.54K	3M 19.01K 17.02K 15.71K 14.21K 26.58K 1.81M 27.01K 187K 74.75K 947K 71.33K 69.81K
Net income	-1.02B -6.45M -5.78M -5.33M -4.82M -9.02M -614M -9.16M -63.58M -25.36M -321M -24.2M -23.69M	-1.14B -7.25M -6.5M -5.99M -5.42M -10.14M -691M -10.31M -71.51M -28.53M -362M -27.22M -26.64M
Net Debt	-3.04B -19.24M -17.23M -15.9M -14.39M -26.9M -1.83B -27.34M -190M -75.67M -959M -72.21M -70.67M	-2.83B -17.91M -16.04M -14.8M -13.39M -25.04M -1.71B -25.45M -177M -70.44M -893M -67.21M -65.78M